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Abstract
Cure models have been widely developed to estimate the cure fraction when some subjects never experience the event
of interest. However these models were rarely focused on the estimation of the time–to–cure i.e. the delay elapsed
between the diagnosis and ”the time from which cure is reached”, an important indicator, for instance to address the
question of access to insurance or loans for subjects with personal history of cancer. We propose a new excess hazard
regression model that includes the time–to–cure as a covariate dependent parameter to be estimated. The model is
written similarly to a Beta probability distribution function and is shown to be a particular case of the non-mixture
cure models. Parameters are estimated through a maximum likelihood approach and simulation studies demonstrate
good performance of the model. Illustrative applications to two cancer data sets are provided and some limitations as
well as possible extensions of the model are discussed. The proposed model offers a simple and comprehensive way to
estimate more accurately the time–to–cure.
Keywords: Cancer; Cure model; Cure time; Net survival; Right to be forgotten.
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1 Background
Since their first formulation by Boag (1949), Mixture Cure Models (MCM) have been widely developed to deal with
survival data including a fraction of subjects who never experience the event of interest (”cured subjects”). Various ways
have been considered by authors (see e.g. Kuk and Chen (1992); Li and Taylor (2002); Zhang and Peng (2009)) to model
the baseline of both the survival function of the ”uncured subjects” and the cure fraction, as well as the covariates effects
on these two quantities, and these led to an extensive development of the MCM. A large review of MCM can be found in
Maller and Zhou (1996) or Klein et al. (2016). In Yakovlev, Tsodikov, and Asselain (1996) a new family of cure models
was introduced, the bounded cumulative hazard cure models also known as non-mixture cure models (NMCM). Suitable
reviews and interpretations of the NMCM were proposed in Chen, Ibrahim, and Sinha (1999); Tsodikov, Ibrahim, and
Yakovlev (2003); and Cooner et al. (2007). Other cure models can be found in the litterature (e.g. Yin and Ibrahim
(2005b); Gu, Sinha, and Banerjee (2011)) and some approaches based on the Box-Cox transformation have been developed
to unify different types of cure models (Yin and Ibrahim (2005a); Zeng, Yin, and Ibrahim (2006); Taylor and Liu (2007)).
For practical use and interpretation of covariates effects, each type of cure model has both advantages and disadvantages
and the issue of cure model selection was addressed for example in Peng and Xu (2012).
Since the late 1990s, cure models have been extended to the framework of the net survival (survival that would be observed
if no death could occur from other causes than the disease of interest) with applications emphasized on cancer data (see
Verdecchia et al. (1998); Yu et al. (2005); Lambert et al. (2006); Andersson et al. (2011) among others).
Let us recall briefly hereafter the basic concept of cure models within the net survival framework. We consider a population
of patients suffering from a disease (say cancer). For a given patient, let denote A the age at diagnosis, X1 (X2 respectively)
the latent variable corresponding to the time elapsed between the diagnosis and the death due to cancer (other causes
respectively), C the right censoring time, ∆ = 1{X < C} the censoring indicator where X = min(X1, X2) and Z a vector
of covariates in Rd. We assume that conditionally on Z, X and C are independent. Then an observation is a quadruple
(T,∆, A,Z), where T = min(X,C) is the observed time since diagnosis then T + A is the observed time since birth. As
it is well known that the age at diagnosis is one of the covariates that influenced the risk of dying from cancer, A is often
also included in the vector of covariates Z. When cause of death is not available, the most used methodology to estimate
the net survival is to assume that conditionally on (A,Z) = (a, z), the observed hazard λobs of T equals the sum of λpop
the known background mortality hazard in the general population (provided by life tables from national statistics) and
λexc the excess hazard due to cancer:
λobs(t|z) = λpop(t+ a|z) + λexc(t|z). (1)
From (1) the link between the survival functions is given by:
Sobs(t|z) = Spop(t+ a|z)× Snet(t|z), (2)
where Sobs (Spop respectively) represents the observed (the background respectively) survival distribution function, and
Snet corresponds to the net survival distribution function, linked to λexc through
Snet(t|z) = exp
{
−Λexc(t|z)
}
= exp
{
−
∫ t
0
λexc(x|z)dx
}
, (3)
with Λexc denoting the cumulative excess hazard function.
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In situations where it is assumed that a fraction of patients will not die from cancer (meaning that lim
t→+∞Λexc(t|z) < +∞
or equivalently that lim
t→+∞Snet(t|z) > 0), the observed subjects can be partitioned into two groups (cured and uncured
subjects). The net survival can then be expressed as a mixture cure model:
Snet(t|z) = pi(z)S1(t|z) + {1− pi(z)}S2(t|z) = pi(z) + {1− pi(z)}S2(t|z), (4)
where S1(t|z) ≡ 1 and S2(t|z) are the net survival functions of cured and uncured patients respectively, the later being a
proper survival distribution. The fraction of cured subjects is pi(z), it depends on covariates z and from (4), is equal to
lim
t→+∞Snet(t|z).
Although cure models have been originally designed to estimate the fraction of cured subjects, they can be used to estimate
another important epidemiological indicator: the time–to–cure i.e. the delay elapsed between the diagnosis and the ”time
from which cure is reached”. Existing cure models do not allow direct estimation of the time–to–cure although this
indicator seems crucial; as for instance it can be used to improve the estimation of the delay for the right to be forgotten
for cancer survivors. Indeed the right to be forgotten provision is an important milestone in European policymaking.
However, it is not universally accessible to cancer survivors across Europe nor does it address all their specific issues.
Cancer survivors are often disadvantaged when applying for essential services such as loans, mortgages or child adoption
(Youth Cancer Europe, 2018).
Different methods to estimate the time–to–cure after fitting a cure model have been proposed: Dal Maso et al. (2014)
defined the time–to–cure as the delay elapsed between the diagnosis and the time from which the 5–year conditional net
survival (defined as the ratio between the net survival at time t+ 5 years and the net survival at time t) becomes greater
than 0.95. In a recent paper Boussari et al. (2018) proposed to consider for a given patient i, the probability pi(t) of
being cured at a given time t after diagnosis knowing that he/she was alive up to t (this probability is nothing but the
ratio between the cure fraction and the net survival at time t); then the time–to–cure is estimated as the delay from which
pi(t) reaches 0.95.
This work considers a natural definition of the time–to–cure, named hereafter time–to–null–excess–hazard (TNEH), as the
delay elapsed between the diagnosis and the time from which the excess hazard becomes null, and proposes a new excess
hazard model where the TNEH is a covariate dependent parameter to be estimated.
We obtain from (3), (4) and the definitions of both the cure fraction and the TNEH:
pi(z) = lim
t→+∞Snet(t|z) = exp
{
−Λexc(τ(z)|z)
}
= exp
{
−
∫ τ(z)
0
λexc(x|z)dx
}
, (5)
where τ(z) is the TNEH depending on the covariates z and λexc(t|z)=0 whenever t > τ(z).
An illustrative plot of the three hazards functions (described in (1)) is given in Figure 1 for an individual diagnosed at 55
or 70 years, assuming that cure is reached and that TNEH depends on the age at diagnosis.
The rest of the paper is organized as follows. In the next Section the new model and its properties are presented as well
as the parameters estimation procedure. We illustrate the performances of the estimators derived from our model through
both a simulation study in Section 3 and applications to survival data from French cancer registries in Section 4. The last
Section is devoted to some concluding remarks summarizing the paper and providing some future related researches.
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Figure 1: Illustrative plot of Observed, Excess and Population hazards functions for an individual diagnosed at 55, 70
years.
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2 New cure model including the TNEH as parameter
2.1 Model specification
Various parametric excess hazard functions have been explored to incorporate the TNEH as a parameter (τ). According
to the definitions of both the TNEH and the excess hazard function, one of the conditions that must be held by any
candidate excess hazard function is to be continuous on [0,+∞), positive on [0, τ) and null from τ . Besides, the function
must have the ability to reproduce a large panel of excess hazard curves encountered, in particular in cancer survival
study. The new excess hazard model is written as follows:
λexc(t|z;θ) =
{
t
τ(z;η)
}α(z;γ)−1{
1− t
τ(z;η)
}β−1
1{0≤t≤τ(z;η)}, (6)
where τ(z;η) > 0 is the TNEH depending on covariates z through the vector of parameters η. Both β > 1 and α(z;γ) > 0
are shape parameters, the later depending on covariates z through the vector of parameters γ. Hence θ = (γ, β,η) is the
vector of parameters to be estimated. Note that we constrained β to be larger than 1 in order to insure the nullity and the
continuity of λexc(t|z;θ) at τ(z;η). The shape of the excess hazard function is therefore dependent of the value of α(z;γ),
either it belongs to (0, 1) and the excess hazard function is non increasing on [0, τ(z;η)] with λexc(t|z;θ) tending to infinity
as t tends to 0, or it is larger than 1 and λexc(t|z;θ) is N-shaped with a maximum located at {α(z;γ)−1}/{α(z;γ)+β−1};
thus because of the linear link between the covariates and the parameters interpreting the effect of covariates in the shape
of excess hazard rate seems easy. Again, the covariates effects on the TNEH (τ(z;η)) are easy to interpret because of the
linear link. In the sequel we refer to the above specified model as the beta–TNEH model.
An example of the beta–TNEH model, with the sex (sex ) and age at the diagnosis of disease (age) as covariates can be
expressed:
λexc(t|z;θ) =
(
t
η0 + η1 × age
)(γ0+γ1×age+γ2×sex)−1(
1− t
η0 + η1 × age
)β−1
1{0≤t≤(η0+η1×age)},
with z = (age, sex) and θ = (γ0, γ1, γ2, β, η0, η1).
As the equation (6) has the structure of a Beta probability density function, we obtain:
The cumulative excess hazard function
Λexc(t|z;θ) =
 τ(z;η)
∫ t
τ(z;η)
0 x
α(z;γ)−1(1− x)β−1 dx if 0 ≤ t ≤ τ(z;η)
τ(z;η)
∫ 1
0
xα(z;γ)−1(1− x)β−1 dx if t > τ(z;η)
= τ(z;η) B
(
α(z;γ), β
)
FBe
( t
τ(z;η)
;α(z;γ), β
)
,
where B denotes the beta function and FBe
(
· ;α(z;γ), β
)
is the cumulative distribution function of a beta distribution
with parameters α(z;γ) and β.
The net survival function
Snet(t|z;θ) = exp
{
−Λexc(t|z;θ)
}
= exp
{
−τ(z;η) B
(
α(z;γ), β
)
FBe
( t
τ(z;η)
;α(z;γ), β
)}
.
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The cure fraction
pi(z;θ) = exp
{
−Λexc
(
τ(z;η)|z;θ
)}
= exp
{
−τ(z;η) B
(
α(z;γ), β
)}
,
hence for covariates that influenced only to the TNEH, it is easy to derive a log-linear link with the cure rate function,
otherwise interpretation of the effect of covariates on the cure rate may be more complex.
Remark 1:
(i) From the above two latest results we obtain: Snet(t|z;θ) =
{
pi(z;θ)
}FBe( tτ(z;η) ;α(z;γ),β)
. We recognize here the
form of the NMCM, then the beta–TNEH model can be seen as a special case of the non-mixture cure models family.
(ii) The issue of covariates incorporation in model (6) (especially in both the two shape parameters α and β) is discussed
in Section 5.
(iii) A huge literature about mixture models identifiability exists. Recently general results about the identifiability of
parameters of a cure model have been obtained by Hanin and Huang (2014). Because of the specificity of our model
we provide in the appendix conditions under which a direct proof of parameters identifiability is obtained.
2.2 Parameters estimation
Maximum Likelihood Estimator (MLE): For a subject i we observe (ti, δi, ai, zi) a realization of (Ti,∆i, Ai,Zi).
The contribution of the ith subject to the log-likelihood is
`(θ|ti, δi, ai, zi) = δi log (λobs(ti, ai|zi,θ))− Λobs(ti, ai|zi,θ)
≡ δi log (λpop(ti + ai|zi) + λexc(ti|zi,θ))− Λexc(ti|zi,θ). (7)
Hence for a sample of n subjects, the MLE satisfies
θ̂ = arg max
θ∈Θ
n∑
i=1
`(θ|ti, δi, ai, zi).
Standard errors of the MLE: It is well known (see e.g. Newey and McFadden (1994)) that
√
n
(
θ̂ − θ0
)
d−→ N (0, I−10 )
as n tends to infinity, where I0 denotes the Fisher information matrix. Using standard martingale methods for counting
processes (see Andersen et al. (2012), Section VI.1), I0 is consistently estimated by Î defined by
Î =
1
n
n∑
i=1
{
δi
∂λexc
∂θ (ti|zi, θ̂)
λpop(ti + ai|zi) + λexc(ti|zi, θ̂)
}⊗2
, (8)
where for a column vector v, v⊗2 = vvT . Thus the standard error of the i-th component of θ̂ is estimated by the square
root of the i-th diagonal entry of n−1Î−1. Moreover the standard errors of other quantities related to θ̂ such as the cure
fraction or the net survival could be derived easily using the delta method.
Remark 2:
In the estimation procedure we use the bound constrained optimization method (L-BFGS-B) of Byrd et al. (1995).
This method takes the advantage of the BFGS algorithm which is shown to have good performance even for non-smooth
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optimization functions (Lewis and Overton, 2009), and uses simple bounds constraints. The optimization algorithm looks
for a θ̂ belonging to a predefined set having the form
k∏
j=1
[θj,min , θj,max] ⊂ Rk where k ∈ N denotes the number of
the parameters. The initial value of θ must belong to the predefined set. A help to set the boundaries is for instance,
informations derived from the model constraints (τ > 0, β > 1, α > 0, see (6)). Note that if any of the estimates equals a
boundary, the predefined set of boundaries must be expanded, followed by a new estimation of the parameters. We provide
in Web Appendix A, the sets of boundaries used in the estimations steps of the following numerical studies (Sections 3
and 4). The L-BFGS-B method is already implemented in the R software, package stats, function optim, (R Core Team,
2019); it requires very short time to run.
3 Simulation study
3.1 Simulated examples
For the data generation algorithm, one can refer to Web Appendix B.
In the following the model complexity was reduced, without loss of generality, by considering only the age at diagnosis as
covariate. Hence we consider the following beta–TNEH model:
λexc(t|a;θ) =
{
t
τ(a;η)
}α(a;γ)−1{
1− t
τ(a;η)
}β−1
1{0≤t≤τ(a;η)}, (9)
where τ(a;η) = η0 + η1 × a∗ and α(a;γ) = γ0 + γ1 × a∗ with a∗ the age at diagnosis standardized using the mean and
the standard deviation of its specified distribution. The vector of unknown parameters, to be estimated from a sample of
size n, is θ = (γ0, γ1, β, η0, η1). The population hazard (expected hazard) is assumed to follow a Weibull distribution, the
scale and shape parameters being 75 and 11 respectively. We considered three different settings for the simulations: one
illustrating a low excess hazard with a short TNEH and a high censoring rate, the second illustrating a high excess hazard
with a moderate TNEH and a low censoring rate, the third illustrating a low excess hazard with a longer TNEH (the
excess hazard becomes null very later and the net survival decreases slowly) and a moderate censoring rate. A graphical
illustration of the discrepancy between the three settings is provided in Web Appendix C.
In the first setting, the vector of true parameters is θ =(2.3, -0.1, 4.8, 5.5, 0.9). The age at diagnosis is uniformly distributed
on intervals [20, 40), [40, 65) and [65, 80], and the proportions of age at diagnosis coming from these three intervals are
0.36, 0.29 and 0.35 respectively. The maximum follow-up time (from diagnosis) is fixed to 15 years and the censoring rate
is about 60%. The MLE performances for several sample sizes n ∈ {250, 500, 1000, 2000} are reported in Table 1, Setting
1. The bias decreases as the sample size n increases and becomes very small for n = 2000. The discrepancies between
the standard deviations of the n estimates (sd) and the empirical means of the standard deviation estimates (se∗) are
low, particularly when n = 2000. Furthermore, the standard deviations are reduced by half when the sample size n is
quadrupled showing that the root–of–n asymptotic convergence rate is reached. For n = 2000 the coverage probabilities
(cp) are close to 0.95 which is another indicator that the MLE behaves well for a sample of size 2000.
Table 1, Setting 2, summarizes the MLE performances from the second setting of simulation. Here the vector of true
parameters is θ =(1.25, -0.05, 3.5, 9, 0.3). The age at diagnosis is uniformly distributed on intervals [20, 50), [50, 70) and
[70, 80], and the proportions of age at diagnosis coming from these three intervals are 0.15, 0.60 and 0.25 respectively.
The maximum follow-up time is fixed to fifteen years and the censoring rate is about 20%. The MLE performances from
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the third setting of simulation are summarized in Table 1, Setting 3, where the vector of true parameters is θ =(3.01,
-0.2, 2.98, 18, 1.2). The age at diagnosis is distributed as in the first setting, the maximum follow-up time is fixed to
twenty–five years and the censoring rate is about 46%. Overall the MLE performances are slightly better in the first
and second settings than in the third setting. The findings from the first simulation setting are consolidated showing
that good estimates can be obtained with the MLE even with moderate sample sizes. Similar results regarding the MLE
performances of the beta–TNEH model were obtained when a more extensive simulation setting was considered with λexc
depending on three covariates: age at diagnosis (continuous), sex, stage of cancer (3 stages = I, II and III). See Web
Appendix D for full details.
Moreover, we checked the beta–TNEH model performances when data were generated from distributions that do not fulfill
the assumptions underlying the new model. We fit the beta–TNEH model to data simulated from another cure model,
the Weibull mixture cure model (a mixture cure model where the survival time of uncured subjects follows a Weibull
distribution) and assess performances of the beta–TNEH model by computing the bias, the root mean square error and
the coverage probability for the cure fraction and for the net survival at time t = 5, 10 and 15 years. Results were
provided in the appendix E. Overall, the beta–TNEH model gives good estimations only if the excess hazard from the
Weibull mixture cure model becomes almost null within the follow-up interval.
We note that when data are generated from a distribution that do not allow cure fraction (i.e. the cure fraction is null),
the beta–TNEH model does not fit the data and gives poor estimations. Indeed, a null cure fraction hypothesis is not
compatible with the beta–TNEH model because it corresponds to a TNEH equal to infinity which is outside of the area
of validity of the model.
3.2 Sensitivity to the initial value in the optimization procedure
In this Section we investigate whether the MLE is robust with respect to the chosen initialization point for likelihood
maximization algorithm. We then have to verify if the maximization algorithm converges to the same value θ̂ whatever
the chosen initial value. We do this through a simulation study considering again the simulated example 1 with B = 1000
repetitions of a sample data of size n = 2000. We generate K initial values of θ following a multiple uniform distribution
on a given space defined by the bounds fixed for the optimization method (see Remark 2). For a given initial value θ
(0)
k ,
k = 1, . . . ,K, we compute the empirical mean θ̂k of the B estimates of θ, obtained from the B simulated samples data
respectively. Then we are interested in the biases between the θ̂k, k = 1, . . . ,K and the true parameter.
Figure 2 shows for K = 30 initial values the boxplots obtained from the K estimates of biases between the empirical
means and the true parameter. The ranges of the computed biases are 0.009, 0.001, 0.048, 0.055 and 0.018 for γ0 = 2.3,
γ1 = −0.1, β = 4.8, η0 = 5.5 and η1 = 0.9 respectively (relative biases vary from 0.4% to 2%). These values are very low
(near 0) which means that the estimates of θ are almost identical whatever the chosen initial value. Thus the estimates
are robust to the choice of the initial point of the optimization algorithm.
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Table 1: MLE performances for various sample sizes based on 1000 simulated samples: mean is the empirical mean, sd is
the empirical standard deviation, se∗ is the mean of the standard errors estimates and cp is the 95% coverage probability.
The censoring rates are about 60% (Setting 1), 20% (Setting 2) and 46% (Setting 3).
Setting 1 n indicators γ0 = 2.3 γ1 = −0.1 β = 4.8 η0 = 5.5 η1 = 0.9
250 mean 2.688 −0.122 4.249 5.084 1.031
sd 0.651 0.325 1.941 2.406 1.264
se∗ 0.618 0.329 2.674 3.143 1.332
cp 0.965 0.988 0.722 0.730 0.858
500 mean 2.457 −0.109 4.595 5.388 0.995
sd 0.341 0.170 1.547 1.900 0.866
se∗ 0.331 0.167 1.747 2.142 0.878
cp 0.959 0.978 0.818 0.808 0.901
1000 mean 2.375 −0.105 4.733 5.487 0.940
sd 0.214 0.110 1.168 1.488 0.629
se∗ 0.211 0.110 1.141 1.400 0.600
cp 0.949 0.961 0.861 0.864 0.915
2000 mean 2.333 −0.100 4.756 5.481 0.918
sd 0.136 0.070 0.723 0.907 0.411
se∗ 0.140 0.070 0.748 0.907 0.400
cp 0.964 0.956 0.920 0.910 0.935
Setting 2 n indicators γ0 = 1.25 γ1 = −0.05 β = 3.5 η0 = 9 η1 = 0.3
250 mean 1.260 −0.052 3.643 9.634 0.447
sd 0.052 0.038 1.377 3.913 1.080
se∗ 0.055 0.039 1.715 4.928 1.201
cp 0.956 0.949 0.851 0.848 0.965
500 mean 1.258 −0.052 3.466 9.027 0.320
sd 0.035 0.025 0.831 2.308 0.664
se∗ 0.037 0.027 0.914 2.557 0.704
cp 0.952 0.959 0.870 0.859 0.961
1000 mean 1.254 −0.051 3.517 9.110 0.331
sd 0.026 0.019 0.601 1.716 0.468
se∗ 0.026 0.019 0.620 1.730 0.474
cp 0.947 0.940 0.905 0.901 0.955
2000 mean 1.252 −0.050 3.487 8.992 0.322
sd 0.018 0.013 0.419 1.160 0.319
se∗ 0.018 0.013 0.415 1.145 0.319
cp 0.953 0.946 0.926 0.921 0.957
Setting 3 n indicators γ0 = 3.01 γ1 = −0.20 β = 2.98 η0 = 18 η1 = 1.2
250 mean 3.198 −0.196 2.843 17.350 1.125
sd 0.390 0.259 0.454 3.513 2.360
se∗ 0.359 0.249 0.434 3.300 2.338
cp 0.952 0.952 0.855 0.829 0.909
500 mean 3.081 −0.202 2.925 17.854 1.265
sd 0.257 0.154 0.329 2.623 1.788
se∗ 0.228 0.158 0.301 2.341 1.659
cp 0.931 0.964 0.880 0.864 0.918
1000 mean 3.046 −0.203 2.943 17.909 1.259
sd 0.162 0.110 0.202 1.664 1.1490
se∗ 0.155 0.108 0.204 1.602 1.138
cp 0.944 0.946 0.921 0.927 0.939
2000 mean 3.021 −0.205 2.967 18.005 1.268
sd 0.109 0.076 0.148 1.177 0.792
se∗ 0.106 0.075 0.142 1.135 0.804
cp 0.949 0.945 0.923 0.926 0.950
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Figure 2: Distributions, based on 1000 simulated samples of size 2000, of the biases when using K = 30 initial values in
the optimization procedure.
4 Illustrative examples on real data
Data were provided by the French network of cancer registries (FRANCIM). The analysis included all patients diagnosed
from 1995 to 2010, aged 15 to 74 years at diagnosis and followed up to June 30, 2013. The follow-up time was censored at
fifteen years. The variable ”age at diagnosis” was categorized as in previous analyzes of the FRANCIM data (Cowppli-Bony
et al., 2016). Thus we define τ(a;η) = η0 +η1×1A1(a)+· · ·+ηJ×1AJ (a) and α(a;γ) = γ0 +γ1×1A1(a)+· · ·+γJ×1AJ (a)
where Aj (0 ≤ j ≤ J) are the age at diagnosis groups and, ηj and γj (1 ≤ j ≤ J) denote respectively the deviations from
the effects η0 and γ0 of age at diagnosis in the reference group A0. In the examples A0 was the group with the largest
size. Model (9) was fitted on two data sets. Expected mortality rates were derived from the observed mortality rates in
the general population available by sex, annual age, year of death, Department of residence and provided by the Institut
National de la Statistique et des Etudes Economiques - France (see Web Appendix F for more details and plots of the
expected mortality).
4.1 Testicular cancer data
We considered data of 2834 subjects diagnosed with testicular cancer, for which excess mortality is low. Death was
observed for 182 subjects (6.4% of the cohort) and the observed median survival time since diagnosis for fatal cases was
2.13 years.
Age at diagnosis was categorized into 4 groups A0 = [15,45), A1 = [45,55), A2 = [55,65) and A3 = [65,75), and the
unknown parameters as well as their standard errors (in brackets) were estimated: γ̂0 = 2.41(0.16), γ̂1 = −0.13(0.18),
γ̂2 = −0.90(0.15), γ̂3 = −0.84(0.28), β̂ = 8.40(2.06), η̂0 = 5.47(1.49), η̂1 = −1.07(0.98), η̂2 = −0.30(0.92), η̂3 =
−2.94(1.64); with a log-likelihood equal to −1152.12, corresponding to an Akaike Information Criterion (AIC) equal to
2322.24.
According to the above estimations we pooled A0 and A1 as well as A2 and A3 and fitted another model with age
at diagnosis categorized into 2 groups A0 = [15,55) and A1 = [55,75). The estimates were then: γ̂0 = 2.39(0.15),
γ̂1 = −0.87(0.14), β̂ = 8.40(2.09), η̂0 = 5.31(1.45) and η̂1 = −0.91(0.81) and the log-likelihood = −1153.87, corresponding
to an AIC = 2317.74. Based on the AIC values we selected the model with 2 age groups.
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Figure 3: Testicular cancer: estimated Excess hazards function (A) by the beta–TNEH model, and estimated Net survivals
functions with their estimated confidence bounds (B and C) from both the PP model (gray lines) and the beta–TNEH
model (black lines).
Figure 3A shows the resulting excess hazard functions while the net survivals from the model with 2 age groups are given
in Figure 3 B and C. The excess hazard peaks around the first year after diagnosis whatever the age group. A significant
discrepancy is observed between the two excess hazards during the two first years after diagnosis; they become almost
identical from two years after diagnosis and close to zero a year later. For each of the age group, we plotted in the
same panel (Figure 3 B and C), the net survival (with confidence bounds) estimation by the beta–TNEH model and the
nonparametric estimation of the net survival (with confidence bounds) by the method of Perme, Stare, and Este`ve (2012),
denoted hereafter PP model. The two curves match well enough whatever the age group showing that the beta–TNEH
model provides a reasonable description of the data. Hence from the testicular cancer data, the cure fraction estimates
followed by their 95% confidence intervals were 0.97 [0.93, 1.00] and 0.86 [0.72, 1.00] in the [15, 55) and the [55, 75) age
at diagnosis groups respectively. The TNEH estimate in the [15, 55) age at diagnosis group is η̂0 = 5.31 years with a 95%
confidence interval equal to [2.45, 8.17]. In the [55, 75) age at diagnosis group, the TNEH estimate is η̂0 + η̂1 = 4.40 years
with a 95% confidence interval equal to [1.91, 6.89].
When fitting a flexible parametric cure model (Andersson et al., 2011) to the testicular cancer data, the derived time–to–
cure estimates from Dal Maso et al. (2014) approach with a cut-off at 0.95 were 0 year and 2.1 years in the [15, 55) and
the [55, 75) age at diagnosis groups respectively.
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4.2 Women pancreatic cancer data
We considered data of 3239 women diagnosed with pancreatic cancer, which is a cancer with a very high excess mortality.
Death was observed for 91.6% of the subjects and half of the deaths were observed at least 0.6 years after diagnosis. The
median and mean age at diagnosis were 66 years and 63.17 years respectively. We fitted a model with the age at diagnosis
categorized into 3 groups A0 = [65,75), A1 = [55,65) and A2 = [15,55).
In the estimation procedure (see Remark 2), the upper bound η0,max for the search of the baseline TNEH (i.e. TNEH for
the reference age group A0) was first fixed to 15 years (corresponding to the maximum follow-up time) and we observed
that the estimate η̂0 equals the upper bound. When varying η0,max up to 40 years, the estimation η̂0 still reached the upper
bound. According to the fixed value for η0,max, the estimations of the other parameters varied but were always different
from both their lower and upper bounds fixed for the estimation procedure. The parameter estimates and standard errors
as well as the log-likelihood of the fitted model for three different values of η0,max (i.e. η0,max = 15, 18, 40 years) are
reported in Table 2. The likelihood increased with η̂0, and for each parameter the standards errors estimates showed that
the derived three confidence intervals overlapped (95% confidence intervals are [9.73, 20.27], [9.68, 26.32] and [−13.37, 93.37]
respectively). Note that for η̂0 = 40 years, we are far out of the follow-up interval (0 to 15 years) meaning that no data
are available for consistent estimations of the parameters; this leads to large standard errors and consequently possible
negative value for the lower bound of the 95% confidence interval, what must be interpreted with caution. For each age
at diagnosis group, the 3 excess hazards corresponding to η̂0 = 15, 18 and 40 years are plotted in Figure 4, panels A, B
and C. Whatever the age group, the 3 curves were very similar showing that the changes in the parameter estimates had
little impact on the corresponding excess hazards. The panels D, E and F of Figure 4 show for the 3 age groups, both the
parametric and the nonparametric estimations of the survival function using the parametric beta–TNEH model and the
nonparametric PP model. Overall whatever the age group, the two curves matched well, meaning that the beta–TNEH
model provided a reliable estimation of the net survival function even if the TNEH was obviously underestimated. Note
that the beta–TNEH model was able to provide satisfactory estimations because of the behavior of the excess hazard
function which was high just after diagnosis, decreased rapidly and became very close to zero before the end of the follow-
up. Although the net survival shows an apparent plateau (often translated as the existence of cure), this example shows a
situation where either the TNEH had a non-finite value or the TNEH was too large, greater than a predefined threshold
(for instance the maximum follow-up time) over which the estimated TNEH has no practical usefulness.
On the other hand, the approaches by both Dal Maso et al. (2014) and Boussari et al.(2018) provided approximations of
the time–to–cure for the women pancreatic cancer data after fitting a flexible parametric cure model (Andersson et al.,
2011). The time–to–cure estimates from the approach of Dal Maso et al. (2014) using a cut-off at 0.95, were 9 years in
both the [15, 55) and the [55, 65) age at diagnosis groups and 10 years in the [65, 75) age at diagnosis group; very close
results were obtained from the approach proposed by Boussari et al. (2018) (see the related paper for more details).
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Figure 4: Women pancreatic cancer: on the left, the beta–TNEH model estimations of the excess hazards (panels A, B
and C, one panel for each age at diagnosis group) when the TNEH’s baseline estimate equals its upper bound fixed to
15 (solid gray line), 18 (dashed black lines) and 40 years (asterisk). On the right, the net survivals estimations for each
age at diagnosis group (panels D, E and F, one panel for each age at diagnosis group) by the PP model with confidence
bounds (solid gray and dotted gray lines) and by the beta–TNEH model (solid black lines) where the TNEH’s baseline
estimate equals 40 years.
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Table 2: Parameter estimates with standard errors in brackets and log-likelihood (LL) when the upper bound of η0 (the
baseline TNEH) is fixed to 15, 18 and 40 years.
η0,max LL γ̂0 γ̂1 γ̂2 β̂ η̂0 η̂1 η̂2
15 −3741.758 0.931 0.074 0.128 6.005 15.000 0.259 −1.959
(0.007) (0.013) (0.018) (1.093) (2.690) (0.962) (1.039)
18 −3737.123 0.933 0.071 0.121 7.156 18.000 0.282 −2.608
(0.007) (0.013) (0.018) (1.712) (4.243) (1.208) (1.390)
40 −3727.847 0.941 0.058 0.100 15.650 40.000 −0.535 −6.850
(0.008) (0.013) (0.021) (10.848) (27.234) (2.930) (5.523)
5 Concluding remarks
The time from which no more death occurs from a disease of interest (such as cancer) is a useful indicator in epidemio-
logical studies, and can help to improve access to insurance and loans for people living with a personal history of cancer.
In this paper we refer to this delay as the time–to–null–excess–hazard (TNEH). While sophisticated models have been
proposed to estimate efficiently the fraction of cured patients, it seems that there is a lack of methods in the literature for
the TNEH estimation.
We proposed a cure model based on a paradigm where the excess hazard function includes the TNEH as a parameter
to be estimated. The proposed beta–TNEH model could be treated as a special case of the NMCM. The simulation
study showed that the beta–TNEH presented good performances regarding the maximum likelihood estimation method.
However we advise to do not use the new method when cure assumption is not reasonable because this will lead to poor
estimations with meaningless results; the beta–TNEH model is really suitable for data showing an excess hazard which
becomes null within the follow-up interval. Existing methods (for instance Dal Maso et al., 2014 and Boussari et al., 2018)
can provide an approximation of the time–to–cure when the excess hazard becomes just relatively low and not necessarily
null. But these methods are based on approximations requiring a choice of a cut-off what could easily be subject of
criticism since the derived time–to–cure estimate could be very sensitive to the predefined value of the cut-off.
Two examples on real data sets were treated and for each of them, the net survival estimated by the beta–TNEH model
was very close to the estimation provided by the nonparametric PP model. With testicular cancer data, robust finite value
of the TNEH was estimated. With women pancreatic cancer data, despite the fact that the excess hazard becomes almost
zero around 10 years after diagnosis, the TNEH’s baseline estimate equals the corresponding upper bound specified for
the optimization procedure, even for a relatively large value of the upper bound (40 years). In such situations, one can
conclude at least that the TNEH is greater than a predefined time T∗ having practical usefulness. Hence treating the
TNEH as a parameter would offer a way to test a cure hypothesis. Of course, by testing the hypotheses ”TNEH ≤ T∗”
versus ”TNEH > T∗”, one could conclude at least whether there is evidence of cure before T∗ or not.
Due to its similarity with a Beta probability distribution function, the new model could reproduce various excess hazard
curves, offers a simple and comprehensible way to handle the TNEH as a model parameter and leads to satisfactory
estimates as shown by the numerical studies. However, in some cases, it would not be flexible enough to capture some
shapes for instance in situation where the excess hazard shows several local extrema before reaching zero. Thus the new
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paradigm should be adapted to more flexible cure models to account for a larger panel of hazard curves. For instance
in the ”flexible” NMCM model proposed by Andersson et al. (2011), the baseline cumulative excess hazard is modeled
by a restricted cubic spline of the time since diagnosis. Instead of fixing arbitrary the last knot of the spline after the
last observed event time as they did, one could consider this knot as a parameter corresponding to the TNEH. However,
treating a spline knot as a model parameter to be estimated is a topic that would need more research.
For model (6) specification purpose we had considered the case where both the two shape parameters α and β were
linked to covariates as well as the case where only β was linked to covariates. Simulations led to unsatisfactory parameter
estimates for these cases (especially when both α and β were linked to the same continuous covariates), probably due to
numerical problems and/or identifiability issue. This kind of problem seemed inherent to cure models. Indeed, Li, Taylor
and Sy (2001) stated that even if a cure model is formally identifiable, a possible near non-identifiability situation could
occur as a flat or irregular likelihood surface for finite samples, with associated numerical problems. Farewell (1982) noted
in parametric cure model a high correlation between the parameter estimates of the incidence part of the model and those
of the latency part of the model, what we thought, could also lead to numerical problems. More generally, Hanin and
Huang (2014) pointed that sharing of covariates between various components of cure models may prevent identifiability
and then good parameter estimates.
Finally we would like to point out that in the beta–TNEH model, the TNEH is assumed to be deterministic, which means
that the model estimates the same value of TNEH for subjects sharing the same characteristics (covariates). A way to
improve our model would be to consider the TNEH as a random effect with a specified common distribution depending
on covariates. This is an ongoing work.
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Appendix: Model identifiability
Let us note Pθ the probability distribution of an observation (T,∆, Z) under the parametric model (6) where for simplicity
we consider that the age at diagnosis A is a component of the covariate vector Z. According to Lehmann and Casella
(1998) the model identifiability holds if θ 7→ Pθ is one–to–one on the parameter space Θ. Let us denote by Z the set
of values taken by the covariates. It is straightforward to verify that identifiability of model (6) is equivalent to the
identifiability of the class of functions
H =
{
(t, z) 7→ λexc(t|z;θ) : [0,+∞)×Z → [0,+∞);θ = (γ, β,η) ∈ Θα × [0,+∞)×Θτ ≡ Θ
}
that is λexc(t|z;θ) = λexc(t|z;θ∗) for all (t, z) in [0,+∞) ×Z implies θ = θ∗ for all (θ,θ∗) ∈ Θ2. Let us introduce two
additional classes of functions:
• A = {z 7→ α(z;γ) : Z → (0,+∞);γ ∈ Θα};
• T = {z 7→ τ(z;η) : Z → (0,+∞);η ∈ Θτ}.
Proposition 1 If the classes of functions A and T are identifiable, then model (6) is identifiable.
Proof. We ever explained that it is sufficient to verify that H is identifiable. Let us consider θ = (γ, β,η) ∈ Θ and
θ∗ = (γ∗, β∗,η∗) ∈ Θ such that λexc(t|z;θ) = λexc(t|z;θ∗) for all (t, z) in [0,+∞)×Z . The supports of λexc(·|z;θ) and
λexc(·|z;θ∗) having to match for all z ∈ Z we have τ(z;η) = τ(z;η∗) for all z ∈ Z , thus η = η∗ since T is identifiable.
As a consequence, for all z ∈ Z and t ∈ (0, τ(z;η)) we have{
t
τ(z;η)
}α(z;γ)−1
×
{
1− t
τ(z;η)
}β−1
=
{
t
τ(z;η)
}α(z;γ∗)−1
×
{
1− t
τ(z;η)
}β∗−1
.
Taking the logarithm of the above equality and using the linear independence of functions t 7→ log
{
t
τ(z;η)
}
and t 7→
log
{
1− tτ(z;η)
}
we obtain β = β∗ and α(z;γ) = α(z;γ∗) for all z ∈ Z . The later result with the identifiability of the
class of functions A leads to γ = γ∗. This finishes the proof. 2
It is easy to check that classes of functions A and T that we used for both the simulation study in Section 3 and the
illustrations on real dataset in Section 4 are identifiable.
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Web Appendix A: boundaries specified in the estimation procedure when using the
L-BFGS-B method
θup denotes the vector of upper bounds, θlo the vector of lower bounds, θ the vector of true
parameters and θ̂ the vector of estimated parameters.
Simulations
Setting 1 θ γ0 = 2.3 γ1 = −0.1 β = 4.8 η0 = 5.5 η1 = 0.9
θlo 0.4 −3 1 1 −5
θup 8 3 12 20 5
Setting 2 θ γ0 = 1.25 γ1 = −0.05 β = 3.5 η0 = 9 η1 = 0.3
θlo 0.4 −3 1 1 −5
θup 8 3 12 20 5
Testicular cancer
θ̂ γ̂0 = 2.39 γ̂1 = −0.87 β̂ = 8.4 η̂0 = 5.31 η̂1 = −0.91
θlo 0.4 −3 1 0.1 −5
θup 6.4 3 10 15 5
Women pancreatic cancer
θ̂ γ̂0 = 0.931 γ̂1 = 0.074 γ̂2 = 0.128 β̂ = 6.005 η̂0 = 15 η̂1 = 0.259 η̂2 = −1.959
θlo 0.4 −5 −5 1 0.1 −10 −10
θup 10 5 5 40 15 10 10
θ̂ γ̂0 = 0.933 γ̂1 = 0.071 γ̂2 = 0.121 β̂ = 7.156 η̂0 = 18 η̂1 = 0.282 η̂2 = −2.608
θlo 0.4 −5 −5 1 0.1 −10 −10
θup 10 5 5 40 18 10 10
θ̂ γ̂0 = 0.941 γ̂1 = 0.058 γ̂2 = 0.100 β̂ = 15.650 η̂0 = 40 η̂1 = −0.535 η̂2 = −6.850
θlo 0.4 −5 −5 1 0.1 −10 −10
θup 10 5 5 40 40 10 10
2
Web Appendix B: data simulation algorithm
In the following U [a, b] denotes the uniform distribution on [a, b] and B(p) denotes the Bernoulli
distribution with parameter p.
(a) Generate n (n ∈ N) realizations of age at diagnosis A (a1, . . . , an) and covariates Z
(z1, . . . ,zn).
(b) Generate n realizations of the lifetime X1 (x11, . . . , x1n) elapsed between the diagnosis
and the death due to cancer: draw n realizations of U (u1, . . . , un) with U ∼ U [0, 1], and
set x1i =
 τ(zi;η)F
−1
Be
(
log(ui)
log{pi(zi;θ)} ;α(zi;γ), β
)
if ui ≥ pi(zi;θ)
∞ if ui < pi(zi;θ)
, for 1 ≤ i ≤ n.
(c) Generate n realizations of the lifetime X2 (x21, . . . , x2n) elapsed between the diagnosis
and the death due to other causes: draw n realizations of U (u∗1, . . . , u
∗
n) with U ∼ U [0, 1],
and set x2i = Λ
−1
pop
[
log
{
u∗i
Spop(ai)
}]
− ai, for 1 ≤ i ≤ n.
(d) Generate n realizations of C1 (c11, . . . , c1n) and n realizations of C2 (c21, . . . , c2n) such that
Cj = Pj × Uj + (1− Pj)× tmax for j ∈ {1, 2} where tmax denotes a predefined maximum
follow-up time, Pj ∼ B(pj) and Uj ∼ U [0, tmax].
Note that C1 describes censoring times corresponding to a mixture of a proportion p1 of
patients who are still alive at the endpoint of the follow-up and are followed less than
tmax, and a proportion 1− p1 of patients followed more than tmax before the endpoint of
the follow-up. C2 describes censoring times corresponding to a mixture of a proportion
p2 of patients who are lost to follow-up, and a proportion 1−p2 of patients followed more
than tmax before the endpoint of the follow-up. Considering that the censoring time C
results from the competing times C1 and C2, the realizations (c1, . . . , cn) of the censoring
time C are then equal to ci = min(c1i, c2i) for 1 ≤ i ≤ n.
(e) Finally the realizations of the survival time T (t1, . . . , tn) and the censoring indicator
∆ (δ1, . . . , δn) are obtained by setting ti = min(x1i, x2i, ci) and δi = 1{min(x1i,x2i)<ci}, for
1 ≤ i ≤ n.
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Web Appendix C: graphical illustration of the simulation settings
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(D)
Excess hazards (A) and Net survivals (C) functions for a patient diagnosed at 55 years;
Time–to–null–excess–hazard (B) and Cure fraction (D) according to age at diagnosis. The
vector of true parameters are θ = (2.3,−0.1, 4.8, 5.5, 0.9), θ = (1.25,−0.05, 3.5, 9, 0.3) and
θ = (3.01,−0.2, 2.98, 18, 1.2) corresponding respectively to the simulation setting 1 (dashed
black lines), the simulation setting 2 (grey lines) and the simulation setting 3 (dashed grey
lines).
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Web Appendix D: Performances of a multivariates beta–TNEH model
We consider the beta–TNEH model (equation (6) in the paper) where λexc depending on three
covariates: age at diagnosis (continuous), sex, stage of cancer (3 stages = I, II and III) with
α depending on age and stage and τ depending on age and sex: α(z1;γ) = γ0 + γ1 × a∗ +
γ2 × 1{stage = II} + γ3 × 1{stage = III} and τ(z2;η) = η0 + η1 × a∗ + η2 × 1{sex = man}; where a∗ is
the age at diagnosis standardized using the mean and the standard deviation of its specified
distribution, z1 = (age, stage), z2 = (age, sex), γ = (γ0, γ1, γ2, γ3) and η = (η0, η1, η2). Hence
θ = (γ,η) is the vector of parameters to be estimated.
Here are some considerations for data generation: The vector of true parameters is θ = (1.6,
–0.02, –0.2, –0.5, 5.4, 7.5, 1.2, 1.5). The age at diagnosis is uniformly distributed on intervals
[20, 40), [40, 65) and [65, 80], and the proportions of age at diagnosis coming from these three
intervals are 0.25, 0.25 and 0.50 respectively; 60% of cases are men; the proportions of stage
I, II and III are 0.50, 0.30 and 0.20. The population hazard is assumed to follow a Weibull
distribution, the scale and shape parameters being 75 and 11 respectively. The maximum
follow-up time (from diagnosis) is fixed to fifteen years and the censoring rate is about 35%.
We generate 1000 repetitions of each sample of size n = {250, 500, 1000, 2000}.
Table:
n ind. γ0 = 1.6 γ1 = −0.02 γ2 = −0.2 γ3 = −0.5 β = 5.4 η0 = 7.5 η1 = 1.2 η2 = 1.5
250 mean 1.689 −0.023 −0.236 −0.572 4.967 7.081 1.296 1.490
sd 0.191 0.056 0.175 0.192 2.044 3.201 1.209 1.498
se∗ 0.190 0.056 0.161 0.185 2.965 4.621 1.433 1.866
cp 0.9680 0.966 0.963 0.967 0.778 0.804 0.873 0.931
500 mean 1.647 −0.022 −0.221 −0.540 5.167 7.259 1.227 1.504
sd 0.118 0.036 0.104 0.117 1.642 2.533 0.873 1.127
se∗ 0.124 0.037 0.104 0.121 1.994 3.059 0.929 1.2409
cp 0.964 0.964 0.955 0.955 0.838 0.818 0.887 0.947
1000 mean 1.622 −0.022 −0.209 −0.517 5.317 7.477 1.238 1.460
sd 0.081 0.025 0.068 0.079 1.267 1.994 0.672 0.819
se∗ 0.083 0.025 0.070 0.082 1.365 2.104 0.649 0.842
cp 0.954 0.945 0.964 0.960 0.878 0.891 0.920 0.944
2000 mean 1.608 −0.020 −0.202 −0.506 5.394 7.534 1.241 1.496
sd 0.056 0.017 0.048 0.055 0.896 1.386 0.446 0.573
se∗ 0.057 0.017 0.048 0.056 0.930 1.428 0.445 0.579
cp 0.947 0.955 0.955 0.950 0.922 0.924 0.935 0.956
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Web Appendix E: Performances of the beta–TNEH model on data simulated from
a Weibull mixture cure model
1. Times to death due to the disease are generated from a Weibull mixture cure model; i.e.
the net survival is written as follows:
Snet(t; Φ) = pi + (1− pi) exp
{
−
(
t
a
)b}
where t is the time since diagnosis, Φ = (pi, a, b) is the vector of parameters with pi the
cure fraction.
The population hazard (expected hazard) is assumed to follow a Weibull distribution,
the scale and shape parameters being 75 and 11 respectively. The age at diagnosis is
uniformly distributed on intervals [15, 58), [58, 65), [65, 70) and [70, 75], with the same
proportion (0.25) of the observations coming from each interval. The maximum follow-up
time (from diagnosis) is fixed to fifteen years and we generate 1000 repetitions of sample
of size 2000. We consider two sets of parameters corresponding to two cases:
Case 1: Φ = (0.10, 0.70, 0.80)
The excess hazard is high just after the diagnosis and decreases to become very close to
zero within the follow-up interval. The censoring rate is about 7%.
Case 2: Φ = (0.50, 1.90, 0.80)
The excess hazard is low excess hazard just after the diagnosis and decreases but remains
less close to zero than the case 1, within the follow-up interval. The censoring rate is
about 26%.
2. We fit the beta–TNEH model (Equation 6 in the paper) without covariate to the simulated
data and assess its performances by computing the bias, the root mean square error and
the coverage probability for the cure fraction, and the net survival at times t = 5, 10 and
15 years.
6
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(C)
Excess hazards (A), excess hazards with focus on very low values (B) and net survivals (C)
functions from the Weibull mixture cure model. The vector of true parameters are Φ =
(0.10, 0.70, 0.80) and Φ = (0.50, 1.90, 0.80) corresponding respectively to the simulation case 1
(black lines) and the simulation case 2 (dashed grey lines).
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(B)
Distributions of the 1000 estimates of the TNEH when the beta–TNEH model is fitted for
each of the 1000 samples of size 2000 generated from the Weibull mixture cure model: (A)
corresponds to Case 1 and (B) corresponds to Case 2.
Table: Beta–TNEH model performances when fitted to data generated from a Weibull mixture
cure model (1000 repetitions of samples of size 2000): ”True” is the value from the true model
which generate the data, ”Bias” is the mean of the biases from the beta–TNEH estimates,
”RMSE” is the root mean square error of the estimates and ”cp” is the coverage probability.
Case 1 Snet(5years) Snet(10years) Snet(15years) Cure rate
True 0.107256 0.100203 0.100008 0.100000
Bias −0.001039 0.001092 0.001268 0.001276
RMSE 0.007982 0.008429 0.008461 0.008463
cp 0.944000 0.941000 0.941000 0.941000
Case 2 Snet(5years) Snet(10years) Snet(15years) Cure rate
True 0.557170 0.511460 0.502697 0.500000
Bias −0.025030 0.003064 0.011230 0.013911
RMSE 0.028640 0.016508 0.019877 0.021511
cp 0.583000 0.920000 0.855000 0.815000
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Web Appendix F: Population mortality hazard in France
Expected mortality rates were derived from the observed mortality rates available by sex, annual
age, year of death (1975 to 2012), Department of residence and provided by the Institut National
de la Statistique et des Etudes Economiques. For a given sex and a given Department, these
observed mortality rates were smoothed for ages above 15 using a Poisson regression model
that included a bidimensional smoothing spline of year and age. Mortality rates were projected
for the years 2013 to 2017 using this same model. Expected mortality rates were also derived
for the whole France. This work has been done by the biostatistical unit of the Hospices Civils
de Lyon, using mgcv package in R software.
Here for illustration purposes, we plot the population mortality hazard at years 1995, 1999,
2003, 2007, 2010 and 2013.
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French population mortality hazard in men (dark dots) and in women (grey dots).
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